Fig. 1. Safety pharmacology results vs. literature-based resources.

a Distribution of AC₅₀ values from SPD by AC₅₀ range, where highly active results are denoted as AC₅₀ < 0.1 µM and inactive results as AC₅₀ ≥ 10 µM. Drug-assay pairs were cross-referenced to resources containing results curated from the biomedical literature: DrugCentral AC₅₀ < 10 µM or target annotated as the MOA in DrugCentral (blue), ChEMBL AC₅₀ < 10 µM (orange), subscription resources AC₅₀ < 10 µM (yellow), or single concentration activity > 50% in either ChEMBL or subscription resources (green). Resources were labeled hierarchically, i.e., activities reported in DrugCentral are mostly available in ChEMBL and other resources. b qualitative comparison of median ChEMBL vs. SPD AC₅₀ values for 5106 drug-assay pairs; SPD results with AC₅₀ qualifier > (AC₅₀ greater than max concentration tested) are shown as ≥10 µM. c quantitative comparison of median ChEMBL vs. SPD AC₅₀ values for 2700 drug-assay pairs where the SPD AC₅₀ qualifier is = (i.e., measurable activity); Pearson R² = 0.48.